The Week Ahead: COS...
Health Care: Drugs
Anthera Pharmaceuticals Inc. (ANTH: NASDAQ)
$0.60 -0.01 | -1.15%
05/24/13 - 03:58 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 0.60 |
| 52 Week High | 3.21 |
| 52 Week Low | 0.49 |
| Avg. Daily Vol. (Mil) | 0.78 |
| Beta (3 year) | 1.35 |
| Share Related Items | |
| Mkt Cap (Mil) | 91.56 |
| Shares Out (Mil) | 152.62 |
| Float (Mil) | 134.44 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 3.80 |
| Current Ratio | 3.80 |
| LT Debt/ Equity | 0.26 |
| Total Debt / Equity | 0.55 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 0.00 |
| Price/Book | 2.75 |
| Price/Cash Flow | -1.10 |
| Per Share Data | |
| Earnings | -0.69 |
| Sales | 0.00 |
| Book Value | 0.22 |
| Cash Flow | -0.55 |
| Business Summary | |
|---|---|
| Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases. | |
| General Information | |
| 25801 Industrial Boulevard
Suite B Hayward, CA 94545 |
|
| www.anthera.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 23 | |
| CEO: Paul F. Truex | |
| Short Interest | |
| Current Month (Mil) | 9.60 |
| Previous Month (Mil) | 9.51 |
| Short Interest Ratio (Days) | 14.80 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -149.80 |
| Return on Investments | -200.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with ANTH
- Portfolio NameUser Type
- ContributorStocks With Big Insider Buy...
- ContributorStocks With Big Insider Buy...
- Usertest1123
- ContributorStocks Under-$10 Setting Up...
- UserStan/Gino
- ContributorStocks With Big Insider Buy...
- UserPoorprae's Stock Picks
- ContributorStocks Under-$10 Moving Hig...
- UserPortfoio1
- ContributorBreakout Stocks Of The Week...
Latest ANTH Headlines from TheStreet
- 5 Stocks Insiders Are Scooping Up 01.30.13 | 12:01 pm
- Top Insider Trades: NVR FIZZ COST ANTH 01.30.13 | 09:01 am
- Biotech Stock Mailbag: Aveo, Anthera, Amarin, MAP Pharma 11.20.12 | 10:11 am
- 5 Stocks Under $10 Set to Trade Higher in November 11.01.12 | 01:11 pm
- 5 Biotech Stocks Under $5 Making Bullish Moves 06.21.12 | 01:06 pm
- 7 Stocks Under $10 Streaking Higher 06.07.12 | 04:06 pm
- 8 Stocks Under $10 Soaring Higher 05.10.12 | 01:05 pm
- Stocks to Watch: ReneSola, UPS, AIG (Update 1) 03.16.12 | 07:03 am
- For Biotech, 'Fail' is Making a Big Comeback 03.12.12 | 08:03 am
- FirstWind IPO -- Gone With the Wind? 10.25.10 | 08:10 am
Press Releases for ANTH
- Anthera Pharmaceuticals Announces Additional Data From Phase 2b PEARL-SC Blisibimod Study - PR Newswire 05.07.13 | 04:05 pm
- Anthera Announces First Quarter 2013 Financial Report And Conference Call - PR Newswire 05.03.13 | 02:05 pm
- Anthera Refinances Existing Debt With New $20 Million Credit Facility And Secures $18.5 Million Committed Equity Financing Facility - PR Newswire 04.05.13 | 05:04 pm
- Anthera Initiates CHABLIS-SC1 Phase 3 Clinical Study In Lupus With Blisibimod - PR Newswire 03.27.13 | 04:03 pm
- Anthera Announces Data From The Phase 2b PEARL-SC Study Will Be Presented At The 10th International Congress On Systemic Lupus Erythematosus - PR Newswire 03.22.13 | 08:03 am
- SHAREHOLDER ALERT: Levi & Korsinsky, LLP Launches An Investigation Into Possible Breaches Of Fiduciary Duty By The Board Of Directors Of Anthera Pharmaceuticals, Inc. In Connection With Executive Compensation - Business Wire 02.13.13 | 11:02 am
- Faruqi & Faruqi, LLP Is Investigating Anthera Pharmaceuticals Incorporated On Behalf Of Its Shareholders - ANTH - PR Newswire 02.13.13 | 08:02 am
- Anthera Pharmaceuticals To Present At The 2013 Leerink Global Healthcare Conference - PR Newswire 02.07.13 | 05:02 pm
- Anthera Pharmaceuticals Announces Departure Of Georgina Kilfoil - PR Newswire 02.05.13 | 08:02 am
- Anthera Pharmaceuticals Announces Completion Of Public Offering Of Common Stock - PR Newswire 01.30.13 | 09:01 am
Partner Headlines for ANTH
- Benzinga's Microcap Movers for Friday August 24, 2012 - Benzinga 08.26.12 | 09:08 am
- Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock; 33M Shares at $1.00/Share - Benzinga 07.19.12 | 09:07 am
- Healthcare Biz Rewind: StemCells DOUBLES Its Value, Anthera POPS - Wall St. Cheat Sheet 07.18.12 | 09:07 am
- Gilead Sciences RECEIVES FDA Approval and 4 Hot Stocks Driving the Market Today - Wall St. Cheat Sheet 07.17.12 | 01:07 pm
- Ultimate Market Recap: Yahoo Down on Mayer's First Day, Mattel Makes Out Well for Q2 - Wall St. Cheat Sheet 07.17.12 | 10:07 am
- 4 Reasons To Buy Anthera Pharmaceuticals - Seeking Alpha 07.16.12 | 09:07 am
- Vertex Pharmaceuticals CRASHES 16% with 3 NASDAQ Top Percentage Losers - Wall St. Cheat Sheet 06.29.12 | 10:06 am
- Today's Market News To Trade On: 5 Stocks Moving On News - Seeking Alpha 06.29.12 | 09:06 am
- Nike SLAPPED with a DOWNGRADE Joining These 3 Stocks - Wall St. Cheat Sheet 06.29.12 | 04:06 am
- Healthcare Business Recap: Orexigen RIDES Arena, Anthera IMPLODES - Wall St. Cheat Sheet 06.28.12 | 08:06 am
